Please see below for a list of search results.
The primary purpose of the health and social care system is to improve outcomes for people who use its services.
The McCracken review looked at how the HTA and HFEA could be more efficient. The HTA has fully incorporated its recommendations.
The HTA was established on 1 April 2005 under the Human Tissue Act 2004 (HT Act) which extends to England, Wales and Northern Ireland.
The Regulators’ Code came into statutory effect in April 2014. It provides a principles-based framework for how regulators should engage with those they regulate.
As a regulator, transparency is not only an aspiration and value, but a statutory duty under the Human Tissue Act. It is also a priority for the Department of Health and Government more generally.
The Human Tissue Authority is committed to promoting equality and diversity, both as an employer and in the carrying out of its public functions to monitor and promote good practice in the sectors that it regulates.
The Human Tissue Authority (HTA) has published licence fee levels for the 2019/20 business year.
The new licence fees come into effect from April 2019, with an increase of 2.7% (the CPI rate in August 2018) to the previous year’s fees.
The Human Tissue Authority (HTA) is an Executive Non-Departmental Public Body (ENDPB) sponsored by the Department of Health and Social Care and as such has a framework agreement.